J&J Submits Application to FDA for Ulcerative Colitis Treatment
Lead: Johnson & Johnson seeks FDA approval for Tremfya as a treatment for adults with ulcerative colitis, based on...
Revolutionize Your Finance News Experience with MorningExpert!
🌟 Custom-Tailored News Just for You: Say goodbye to information overload. Our cutting-edge filtering technology curates your feed to perfection, delivering only the finance news that matches your interests and professional ambitions.
🔔 Flexible Updates, Your Way: How do you like your updates? Choose from instant app notifications, email digests, or captivating video summaries to stay informed on your own terms.
🎥 Engaging Video Summaries: Pressed for time? Let our expert anchors brief you with video summaries, giving you the essence of each news piece in minutes.
🚨 Personalized Alerts: Never miss out on what matters most. Set custom alarms for topics you’re passionate about, and be the first in the know.
📹 Create Your Own Video Content: Dive deeper into the topics that intrigue you with personalized videos. Generated on demand, these videos bring your chosen keywords or interests to life.
MorningExpert is more than a news app; it’s a dedicated companion for anyone passionate about finance. Whether you’re a seasoned professional, an avid enthusiast, or simply eager to stay updated with the finance world, our app ensures you’re always ahead of the curve.
With features designed to make staying informed effortless and enjoyable—such as custom alarms and on-demand video content—navigating the finance landscape has never been simpler or more tailored to your needs.
Transform the way you consume finance news. Download MorningExpert now and step into a world of precision-informed finance knowledge. Your next-level finance journey starts here!
acquisition adjusted earnings AI analysts apple artificial intelligence Bitcoin CEO China demand dividend Donald Trump Dow Jones Industrial Average earnings economy extreme event FactSet Federal Reserve fourth quarter growth guidance hamas inflation interest rates investment investors Israel Microsoft net income net profit Nvidia profit revenue revenue growth S&P 500 sales shareholders shares stock stock market stocks tesla third quarter Trump Wall Street
Lead: Johnson & Johnson seeks FDA approval for Tremfya as a treatment for adults with ulcerative colitis, based on...
Lead: Acelyrin's shares soar 10% to $8.20 as the biopharmaceutical company reveals promising results from a clinical trial for...
**Lead:** MoonLake Immunotherapeutics' shares surge in premarket trading after announcing promising results from a Phase 2 study of sonelokimab...
Rani Therapeutics Holdings has announced positive results from its Phase 1 clinical study of RT-111, a RaniPill capsule containing...
Fortrea, a contract research organization, is disputing the accuracy of statements made by Acelyrin regarding two clinical trials on...
In a surprising move, biopharmaceutical company iBio has announced a 20-to-1 reverse stock split, causing shares to decline by...
Shares of Acelyrin, a biopharmaceutical company, plummeted 11% after it revealed a programming error in its drug trial for...
Shares of Aclaris Therapeutics plummeted over 85% in premarket trading today after the company's drug candidate, zunsemetinib, failed to...
Aclaris Therapeutics, a biopharmaceutical company, saw its shares plummet nearly 90% and hit an all-time low after abandoning its...
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, is discontinuing the development of zunsemetinib, one of its lead clinical assets, after...